SPOTLIGHT: Averion expands through buyout


Averion International has acquired Hesperion, a Swiss CRO, for $36.2 million. Averion now has 14 offices in 10 countries and has doubled its full-time employee base to approximately 400. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.